Hikma Sets Date for 2025 Full-Year Results Announcement

Hikma Pharmaceuticals ( (GB:HIK) ) has issued an announcement.

Hikma Pharmaceuticals has scheduled the release of its financial results for the year ended 31 December 2025 on 26 February 2026, providing investors and analysts with an upcoming view of the company’s recent performance. The group will make a recorded results presentation and slide deck available on its website from 7:00am GMT and will host a live Q&A call for analysts at 9:30am GMT, underlining its continuing emphasis on transparency and engagement with the financial community.

The most recent analyst rating on (GB:HIK) stock is a Buy with a £2300.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.

Spark’s Take on GB:HIK Stock

According to Spark, TipRanks’ AI Analyst, GB:HIK is a Outperform.

Hikma Pharmaceuticals’ overall stock score is driven by strong financial performance and attractive valuation. While technical indicators suggest a bearish trend, the company’s strategic achievements and executive confidence provide a positive outlook. Earnings call insights and corporate events further support the stock’s potential for growth.

To see Spark’s full report on GB:HIK stock, click here.

More about Hikma Pharmaceuticals

Hikma Pharmaceuticals is a London-listed pharmaceutical group that develops, manufactures and markets a broad range of generic and specialty medicines, with a focus on serving global markets through both injectable and oral products.

Average Trading Volume: 774,953

Technical Sentiment Signal: Sell

Current Market Cap: £3.37B

See more insights into HIK stock on TipRanks’ Stock Analysis page.